EligibleTrials

Study of the Disease Process of Lymphangioleiomyomatosis

Recruiting · NCT00001465 · Observational (researchers observe without assigning treatment) · Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI)

View the official record on ClinicalTrials.gov →
Lung cancerMultiple sclerosis

Interventions studied

Toshibia Aquilion One CT

What this trial is about

Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. This study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy. Researchers intend to identify the proteins and genes that contribute to the process of lung destruction in affected individuals.

Who can take part

Age range
16 Years to 100 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed across 1 US state.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.